The available evidence does not establish that compounded semaglutide drops taken under the tongue lead to weight loss in people. Studies of how semaglutide tablets and injections are absorbed apply to the products tested. They cannot tell us how much of a compounded drop reaches the bloodstream.[1][2][3][5]
How the approved tablets work
The U.S. Rybelsus and Ozempic tablet label says both contain an absorption enhancer called SNAC and are absorbed mainly in the stomach. The Wegovy label covers an injection and a swallowed tablet. These products have their own clinical data, which do not establish the effects of a formulation used under the tongue.[1][5]
The FDA concerns about compounded semaglutide apply to claims about product safety and effectiveness. FDA does not approve compounded drugs or review them for safety, effectiveness, or quality before marketing. If clinical data are cited, check whether the study tested that specific formulation in people.[6]
What animal studies measured
In a single-dose rat study, experimental formulations given under the tongue had about 0.29% to 0.34% of the dose-adjusted exposure of the injection. The authors worked for a supplier to compounding pharmacies. A different study used an investigational film in minipigs and found less weight gain than with placebo. The animals still gained weight. Neither study evaluated a marketed compounded drop in people.[2][3]
What online listings can show
A 2025 search of compounding websites found 17 single-ingredient semaglutide or tirzepatide products in formulations that differed from the approved versions. Of those listings, 82% were for products used under the tongue. The researchers reviewed product offerings and did not test their absorption or effect on weight.[4]